ASTH Relative Valuation
ASTH's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ASTH is overvalued; if below, it's undervalued.
Historical Valuation
Astrana Health Inc (ASTH) is now in the Undervalued zone, suggesting that its current forward PE ratio of 12.76 is considered Undervalued compared with the five-year average of 37.00. The fair price of Astrana Health Inc (ASTH) is between 33.92 to 94.59 according to relative valuation methord. Compared to the current price of 24.95 USD , Astrana Health Inc is Undervalued By 26.45%.
Relative Value
Fair Zone
33.92-94.59
Current Price：24.95
26.45%
Undervalued
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
1.61
P/B
Median3y
2.91
Median5y
3.77
4.16
FCF Yield
Median3y
2.79
Median5y
3.30
Competitors Valuation Multiple
The average P/S ratio for ASTH's competitors is 1.14, providing a benchmark for relative valuation. Astrana Health Inc Corp (ASTH) exhibits a P/S ratio of 0.36, which is -68.72% above the industry average. Given its robust revenue growth of 53.43%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
FAQ
Is Astrana Health Inc (ASTH) currently overvalued or undervalued?
What is Astrana Health Inc (ASTH) fair value?
How does ASTH's valuation metrics compare to the industry average?
What is the current P/B ratio for Astrana Health Inc (ASTH) as of Jul 17 2025?
What is the current FCF Yield for Astrana Health Inc (ASTH) as of Jul 17 2025?
What is the current Forward P/E ratio for Astrana Health Inc (ASTH) as of Jul 17 2025?